Market Research Logo

Schizophrenia - Pipeline Review, H1 2015

Schizophrenia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H1 2015’, provides an overview of the Schizophrenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Schizophrenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Schizophrenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Schizophrenia Overview
Therapeutics Development
Schizophrenia - Therapeutics under Development by Companies
Schizophrenia - Therapeutics under Investigation by Universities/Institutes
Schizophrenia - Pipeline Products Glance
Schizophrenia - Products under Development by Companies
Schizophrenia - Products under Investigation by Universities/Institutes
Schizophrenia - Companies Involved in Therapeutics Development
Schizophrenia - Therapeutics Assessment
Drug Profiles
Schizophrenia - Recent Pipeline Updates
Schizophrenia - Dormant Projects
Schizophrenia - Discontinued Products
Schizophrenia - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Schizophrenia, H1 2015
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2015
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by Adamed Sp. z o.o., H1 2015
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2015
Schizophrenia - Pipeline by AGY Therapeutics, Inc., H1 2015
Schizophrenia - Pipeline by Alkermes Plc, H1 2015
Schizophrenia - Pipeline by Amgen Inc., H1 2015
Schizophrenia - Pipeline by Angita B.V., H1 2015
Schizophrenia - Pipeline by ANP Technologies, Inc., H1 2015
Schizophrenia - Pipeline by Ascendis Pharma A/S, H1 2015
Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2015
Schizophrenia - Pipeline by Athersys, Inc., H1 2015
Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H1 2015
Schizophrenia - Pipeline by BioCrea GmbH, H1 2015
Schizophrenia - Pipeline by Biotie Therapies Corp., H1 2015
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Schizophrenia - Pipeline by Cerecor Inc., H1 2015
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2015
Schizophrenia - Pipeline by Curemark, LLC, H1 2015
Schizophrenia - Pipeline by Delpor, Inc., H1 2015
Schizophrenia - Pipeline by Domain Therapeutics SA, H1 2015
Schizophrenia - Pipeline by Dong Wha Pharma Co., Ltd., H1 2015
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2015
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2015
Schizophrenia - Pipeline by Eli Lilly and Company, H1 2015
Schizophrenia - Pipeline by Evotec AG, H1 2015
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by Galenea Corp., H1 2015
Schizophrenia - Pipeline by GeNeuro SA, H1 2015
Schizophrenia - Pipeline by Genovate Biotechnology Co., LTD., H1 2015
Schizophrenia - Pipeline by Gilead Sciences, Inc., H1 2015
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015
Schizophrenia - Pipeline by GP Pharm, S.A., H1 2015
Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2015
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2015
Schizophrenia - Pipeline by Heptares Therapeutics Limited, H1 2015
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015
Schizophrenia - Pipeline by Indivior Plc, H1 2015
Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H1 2015
Schizophrenia - Pipeline by IntelGenx Corp., H1 2015
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Schizophrenia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015
Schizophrenia - Pipeline by Jiangsu Nhwa Pharma Corporation, H1 2015
Schizophrenia - Pipeline by Johnson & Johnson, H1 2015
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by KemPharm, Inc., H1 2015
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2015
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2015
Schizophrenia - Pipeline by Lohocla Research Corporation, H1 2015
Schizophrenia - Pipeline by Luye Pharma Group Ltd., H1 2015
Schizophrenia - Pipeline by Merck & Co., Inc., H1 2015
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H1 2015
Schizophrenia - Pipeline by NeurOp, Inc, H1 2015
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H1 2015
Schizophrenia - Pipeline by Nuvo Research Inc., H1 2015
Schizophrenia - Pipeline by Omeros Corporation, H1 2015
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Schizophrenia - Pipeline by Peptron, Inc., H1 2015
Schizophrenia - Pipeline by Pfizer Inc., H1 2015
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H1 2015
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H1 2015
Schizophrenia - Pipeline by Saniona AB, H1 2015
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Schizophrenia - Pipeline by SK Chemicals Co., Ltd., H1 2015
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H1 2015
Schizophrenia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Schizophrenia - Pipeline by Targacept, Inc., H1 2015
Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H1 2015
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H1 2015
Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H1 2015
Schizophrenia - Pipeline by Zogenix, Inc., H1 2015
Schizophrenia - Pipeline by Zysis Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2015
Schizophrenia - Dormant Projects, H1 2015
Schizophrenia - Dormant Projects (Contd..1), H1 2015
Schizophrenia - Dormant Projects (Contd..2), H1 2015
Schizophrenia - Dormant Projects (Contd..3), H1 2015
Schizophrenia - Dormant Projects (Contd..4), H1 2015
Schizophrenia - Dormant Projects (Contd..5), H1 2015
Schizophrenia - Dormant Projects (Contd..6), H1 2015
Schizophrenia - Dormant Projects (Contd..7), H1 2015
Schizophrenia - Dormant Projects (Contd..8), H1 2015
Schizophrenia - Dormant Projects (Contd..9), H1 2015
Schizophrenia - Dormant Projects (Contd..10), H1 2015
Schizophrenia - Dormant Projects (Contd..11), H1 2015
Schizophrenia - Discontinued Products, H1 2015
Schizophrenia - Discontinued Products (Contd..1), H1 2015
Schizophrenia - Discontinued Products (Contd..2), H1 2015
Schizophrenia - Discontinued Products (Contd..3), H1 2015
Schizophrenia - Discontinued Products (Contd..4), H1 2015
List of Figures
Number of Products under Development for Schizophrenia, H1 2015
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report